No Data
Hong Kong stocks movement | China-Affiliated Brokerages collectively rise as Institutions state that mergers and acquisitions in the brokerage industry remain a configuration direction, and the high growth trend in performance for the first half of the ye
China-Affiliated Brokerage stocks collectively rose. As of the time of writing, China International Capital Corporation (03908) increased by 4.2%, reaching HKD 15.86; China Merchants (06099) rose by 4.1%, reaching HKD 15.2; CSC (06066) climbed by 3.8%, reaching HKD 10.38; GTJA (02611) rose by 3.68%, reaching HKD 12.96; China Galaxy (06881) increased by 3.44%, reaching HKD 8.41.
Guotai Junan Securities Co., Ltd.'s (SHSE:601211) Shares Lagging The Market But So Is The Business
[Brokerage Focus] CITIC SEC: Coordinating market investment and financing reforms, gradually moving towards the new normal of IPOs.
Jingwu Financial News | CITIC SEC stated that the normalization of IPOs is not only a reform direction that aligns with the balance of investment and financing but also an essential role of the Capital Markets in serving the real economy. The long-term returns of the Stocks market cannot rely solely on abundant liquidity; introducing high-quality growth companies through IPOs is the foundation for the market's long-term stability. Given the ample liquidity levels in the A-share market in the past five months, under the condition of no relaxation of listing standards, a moderate increase in IPO supply will not burden the market. The firm expects that with the active drive of IPOs in the mainland and Hong Kong markets, the Huaan CSI All Share Investment Banking & industry is likely to benefit from its light-asset investment banking Business and high ROE business characteristics.
Express News | Guotai Junan Securities Says Its Merger With Haitong Securities to Enter Share Swap Stage
GTJA: Maintains SKB BIO-B "Shareholding" rating as core products enter the commercialization harvest period.
GTJA released a Research Report stating that SKB BIO-B (06990) maintains a "Shareholding" rating. The company's core products have entered a commercial harvest period, with multiple important clinical data about to be disclosed, and overseas clinical layout accelerating. Considering the uncertainty of the confirmation timeline for milestone payments from overseas partner MSD, the revenue forecasts for 2024-2026 have been adjusted to 1.732/1.67/2.666 billion yuan (previously 1.72/1.924/2.534 billion yuan). GTJA's main viewpoints are as follows: products are being continuously approved for market launch, and the first domestically produced TROP2ADC is expected to lead in clinical trials.
Haitong Securities to Delist From Hong Kong, Shanghai on March 4
Jimmy w : Does this mean Futu will take off?
bullrider_21 OP Jimmy w : I think after a consolidation, it will rise again.